Antiphospholipids antibodies in type II DM patients

Abstract

AbstractThe Aims of the present study are to determine the presence of antiphospholipid antibodies (Lupus anticoagulant, IgM and IgG anticardiolipin antibodies) in a series of patients with type II diabetes mellitus and to assess any correlation between cardiovascular complication of diabetes mellitus and presence of antiphospholipid antibodies. Patients and methods: A total number of 84 patients who were known case of type II diabetes mellitus were studied during a period of 5 months extended from June 2009 to October 2009 while attending the out patient clinic in Karbala, Iraq. Forty two healthy volunteers of 56 years mean age served as a control group. Blood were aspirated from all patients and control group for lupus anticoagulant (Kaolin clotting time / Kaolin clotting time index) and anticardiolipin (IgM and IgG) antibodies estimation. Result: Total number of 84 studied patients with type II diabetes mellitus, 59 were females and 25 were males with mean age of 52 ± 4 years. Two diabetic patients have lupus anticoagulant positive result; in contrast no case in control healthy group had lupus anticoagulant positive result. One case of diabetics had positive anticardiolipin IgM and IgG antibody, in addition to another patient had anticardiolipin IgG antibody in contrast to single case of control group with IgG anticardiolipin positive result. The data obtained from those 84 cases showed no statistically significant parameters of antiphospholipid antibodies (Lupus anticoagulant, IgM and IgG anticardiolipin antibodies) between the control & patients groups and there was no significant correlation between cardiovascular complicated and uncomplicated groups regarding antiphospholipid antibodies.Conclusions: Presence of antiphospholipid antibodies is exceptional in patients with type II diabetes mellitus, and has no role in the pathogenesis of diabetic thrombotic complications.Further studies with high series of cases and follow-up should be elucidating the presence of antiphospholipid antibodies in type II diabetes mellitus and its macro and microvascular complications.